Cai Fu Zai Xian·2026-02-02 07:06Core Insights - The Chinese duty-free industry is experiencing a turning point due to improved policies, rising consumer confidence, and reduced external competition pressures, marking the establishment of a bottoming out phase for the industry [1][10]. Group 1: Industry Trends - The decline in the duty-free sector post-2020 was influenced by multiple factors, including increased competition from high commission models in Japan and South Korea, reduced consumer spending due to fluctuating income expectations, and limited supply from existing duty-free stores [1]. - Since 2023, government policies aimed at stimulating consumption have been effective, leading to a gradual recovery in consumer sentiment, particularly among middle to high-income households [3]. - The expansion of China's visa-free travel and cultural influence is enhancing the attractiveness of "China Travel" among international tourists, contributing to the recovery of passenger flow in port and city duty-free shops [6]. Group 2: Market Expansion - The duty-free market is set for rapid expansion with the introduction of 41 new port duty-free stores, as announced by the Ministry of Finance and other departments, aimed at increasing market scale through reasonable competition [6][10]. - The core duty-free market in Hainan is benefiting from favorable policies, with significant increases in sales figures, such as a 34.86% year-on-year growth in shopping amounts during the first week of new regulations [8]. Group 3: Company Insights - China Duty Free Group (601888) holds over 85% market share in Hainan's duty-free market, benefiting from zero tariffs and low corporate tax rates, with projected revenue growth from 45 billion to 60-65 billion yuan by 2026 [12]. - Hainan Airlines (600515) controls over 90% of air passenger flow in Hainan, with an increase in international routes expected to drive growth in air passenger and cargo transport [13]. - Hainan Haoyao (000566), while not a traditional duty-free operator, benefits from favorable policies in the biopharmaceutical sector, with a projected peak revenue contribution of 15 billion yuan from innovative drugs by 2026 [13].